Contravir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Contravir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

On February21, 2018 ContraVir Pharmaceuticals,Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the“Meeting”). At the Meeting, the Company’s stockholders (i)re-elected Gary S. Jacob, James Sapirstein, Timothy Block, John P. Brancaccio, Arnold Lippa, Thomas Adams and Tamar Howson as directors of the Company’s Board, (ii)ratified the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December31, 2018 and (iii)approved an amendment to the Company’s 2013 Equity Incentive Plan to increase the number of shares issuable thereunder to 10,700,000 shares from 7,700,000 shares.

As of January23, 2018, the record date for the Meeting, there were 81,017,863shares of our common stock outstanding (including 2,166,934shares of common stock issuable upon conversion of the SeriesA Preferred Stock), of which at least 41,080,732 shares were represented at the Meeting, or approximately 50.706% of the total outstanding, which was sufficient to constitute a quorum.

Set forth below are the final voting results for each of the proposals:

Proposal No.1- Election of Directors

Name

VotesFor

VotesAgainst

VotesAbstained

Gary S. Jacob

18,898,373

3,520,340

James Sapirstein

21,072,469

1,346,244

John P. Brancaccio

18,987,750

3,430,963

Arnold Lippa

19,205,607

3,213,106

Thomas Adams

19,032,795

3,385,918

Timothy Block

21,533,713

885,000

Tamar Howson

20,407,601

2,011,112

Proposal No.2 — Ratification of the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December31, 2018.

VotesFor

VotesAgainst

VotesAbstained

40,335,615

541,393

203,723

Proposal No.3 — Approval of Amendment to 2013 Equity Incentive Plan increasing the number of shares issuable thereunder to 10,700,000 from 7,700,000

VotesFor

VotesAgainst

VotesAbstained

15,602,694

6,517,708

298,311

Item 8.01Other Events.

A copy of the press release issued by the Company with respect to the Meeting is attached hereto as Exhibit99.1.

With respect to Proposal 4 regarding the authorization of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock at a specific ratio, within a range of 1-for-5 and 1-for-20, to be determined by the Board of Directors in its sole discretion and effected, if at all, on or before February21, 2019, the Annual Meeting was adjourned to March9, 2018, at 9:00 a.m.Eastern Time. The adjourned stockholder meeting will be held at the Company’s offices, located at 399 Thornall Street, First Floor, Edison, New Jersey 08837. The purpose of the adjournment is to allow additional time for the Company’s stockholders to vote on Proposal 4.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

99.1

ContraVir Pharmaceuticals,Inc. Press Release dated February21, 2018


ContraVir Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a18-6624_1ex99d1.htm EX-99.1 Exhibit 99.1     ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9,…
To view the full exhibit click here

About Contravir Pharmaceuticals,Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.